Cell Therapy News/Articles, page-16638

I wouldn't be surprised if Novartis come back into the picture on the back of an FDA approval for Remestemcel-L and / or a positive CHF FDA meeting (I would prefer they didn't but nothing I do or say will change that - money talks as they say) .... cardiovascular being one of the main five therapeutic areas of focus of its R & D activities moving forward.


"In recent quarters, Novartis has decided to make five therapeutic areas—cardiovascular, hematology, solid tumors, immunology and neuroscience—and a small clutch of technology platforms the focus of its R&D activities."


https://www.fiercebiotech.com/biotech/novartis-axes-10-pipeline-programs-narrow-rd-focus

Novartis prunes assets, axing 10% of pipeline programs to narrow R&D focus


Novartis has undertaken an old-fashioned decimation of its pipeline. The Swiss drugmaker has decided to dump or out-license 10% of its R&D projects to narrow its sights on five core therapeutic areas and focus investment on its most promising programs within those spaces.


In recent quarters, Novartis has decided to make five therapeutic areas—cardiovascular, hematology, solid tumors, immunology and neuroscience—and a small clutch of technology platforms the focus of its R&D activities. More recently, disclosures about partnered programs that Novartis is dumping gave hints that an overhaul was underway. Now, Novartis has shared a full look at its slimmed-down pipeline.